Male pattern baldness — androgenetic alopecia — affects roughly half of men by age 50, according to the British Association of Dermatologists (BAD). It is one of the most common reasons men visit a pharmacy looking for a treatment they can start without a GP appointment. Community pharmacists are well placed to advise on what works, what does not, and when the pattern of hair loss warrants medical investigation.

What causes it

Androgenetic alopecia is driven by dihydrotestosterone (DHT), a metabolite of testosterone produced by the enzyme 5-alpha reductase. DHT miniaturises hair follicles in genetically susceptible individuals, progressively shortening the growth phase until the follicle produces only fine vellus hair. The pattern is characteristic: receding hairline, thinning crown, and eventual confluence. The Norwood-Hamilton scale classifies severity from I (minimal recession) to VII (extensive loss).

The condition is not medically harmful, but its psychological impact is well documented. A 2019 systematic review in the Journal of Cosmetic Dermatology found significant associations between androgenetic alopecia and reduced quality of life, anxiety, and depression.

Pharmacy treatment options

Two treatments have robust clinical evidence: minoxidil (available OTC) and finasteride (prescription-only).

Minoxidil — the pharmacy medicine

Minoxidil topical solution (2% and 5%) and foam (5%) are classified as pharmacy medicines (P) in the UK, meaning they can be sold without a prescription under pharmacist supervision.

How it works: the exact mechanism is not fully understood, but minoxidil prolongs the anagen (growth) phase and increases follicular size. It does not affect DHT levels.

Evidence: a Cochrane review (2012) found that 5% minoxidil was superior to 2% for vertex baldness, with moderate-quality evidence. The 5% formulation showed a mean increase of approximately 18.6 more hairs per cm² than placebo at 12 months. Effect sizes are modest — minoxidil slows loss and may regrow some hair, but it does not reverse advanced baldness.

Counselling points for pharmacists:

• Set realistic expectations. Visible results take three to six months of consistent twice-daily application. If there is no improvement after 12 months, the treatment is unlikely to work for that individual.
• Application technique. Apply 1ml (solution) or half a capful (foam) to dry scalp twice daily. Massage in gently. Wash hands afterwards to avoid unwanted hair growth on other areas.
• Shedding phase. Some patients experience increased hair shedding in the first two to eight weeks as miniaturised hairs are pushed out by new growth. This is temporary and a sign the treatment is working. Patients should be warned about this to prevent premature discontinuation.
• Stopping treatment. Hair regained with minoxidil is maintained only while the treatment continues. Stopping will result in gradual return to the pre-treatment pattern over three to six months.
• Side effects. Scalp irritation and contact dermatitis are the most common. The foam formulation may be better tolerated than the solution (which contains propylene glycol). Systemic absorption is minimal with correct application.
• Contraindications. Minoxidil should not be supplied to men under 18 or those with unexplained hair loss, sudden patchy loss (possible alopecia areata), or scalp inflammation.

Finasteride — prescription only

Finasteride 1mg daily is a prescription-only medicine (POM) in the UK. It inhibits type II 5-alpha reductase, reducing DHT levels by approximately 70%.

Evidence: the pivotal trials (Kaufman et al., 1998) demonstrated that finasteride 1mg daily increased hair count by a mean of 107 hairs per cm² over two years compared to a decline of 38 hairs in the placebo group. It is more effective than minoxidil for frontal recession.

Why it matters for pharmacists: although pharmacists cannot supply finasteride for hair loss, they are frequently asked about it. Key points:

• Sexual side effects. Decreased libido, erectile dysfunction, and reduced ejaculate volume occur in approximately 1-2% of users in clinical trials. These are usually reversible on discontinuation, though rare reports of persistent effects exist (the clinical significance of "post-finasteride syndrome" remains debated in the literature).
• PSA testing. Finasteride halves PSA levels. Men undergoing prostate screening should inform their doctor they are taking it, as the result must be doubled for interpretation.
• Pregnancy exposure. Finasteride is teratogenic — women who are or may become pregnant must not handle crushed or broken tablets due to the risk of absorption through the skin affecting male fetal development.

What does not work

Pharmacists are frequently asked about alternative remedies. The evidence for most is weak or absent:

Pharmacists should be straightforward: minoxidil and finasteride are the only treatments with strong evidence. Everything else is either unproven or disproven.

When to refer

Not all hair loss is androgenetic alopecia. Pharmacists should refer patients who present with:

• Sudden onset — hair loss developing over days to weeks rather than months to years
• Patchy loss — circular bald patches suggest alopecia areata, which requires dermatological assessment
• Scalp inflammation — redness, scaling, or scarring may indicate a scarring alopecia, which is irreversible if untreated
• Diffuse thinning without pattern — may indicate telogen effluvium (often post-illness, post-surgery, or medication-related) or thyroid disease
• Associated symptoms — weight change, fatigue, or other systemic symptoms suggesting an underlying condition
• Age under 18 — unusual to develop significant androgenetic alopecia before adulthood; consider other causes
• Psychological distress — significant anxiety or depression related to hair loss warrants GP referral for support

The pharmacy role in men's health

Hair loss consultations are an opportunity for broader men's health engagement. Men who visit the pharmacy for minoxidil may not have seen a GP recently. Pharmacists can use the consultation to signpost blood pressure checks, ask about cardiovascular risk factors, or encourage NHS Health Checks for eligible patients.

PharmSee tracks 1,715 active pharmacy vacancies across England. For pharmacists interested in dermatology-adjacent roles, NHS Jobs listings include positions in dermatology clinics and specialist skin services. The salary guide provides benchmarking data for roles with specialist clinical components.

Sources

• British Association of Dermatologists: patient information on androgenetic alopecia
• Cochrane review: Minoxidil for androgenetic alopecia (2012)
• Kaufman et al., JAAD 1998: finasteride 1mg pivotal trial data
• BNF: minoxidil (topical), finasteride monographs
• NICE Clinical Knowledge Summary: alopecia — androgenetic
• PharmSee vacancy tracker: 1,715 active roles as of 15 April 2026